Fidasimtamab, also known as DLTV – 1504, represents an innovative strategy in the battle against multiple myeloma. This therapy a targeted antibody designed to together engage CD3-positive lymphocytes and https://fidasimtamabforlabuse955188.pointblog.net/fidasimtamab-the-promising-treatment-in-advanced-plasma-cell-therapy-95691068